Form 4: Kymera Therapeutics COO Jeremy Chadwick Reports Acquisition of Stock Options and Restricted Stock Units

Chief Operating Officer of Kymera Therapeutics, Jeremy Chadwick, reports the acquisition of stock options and restricted stock units.

Summary

• On March 1, 2024, Jeremy Chadwick, the Chief Operating Officer of Kymera Therapeutics, acquired 13,425 restricted stock units (RSUs) and stock options for 80,548 shares of common stock.
• The RSUs vest in three equal annual installments starting March 1, 2024, contingent upon continued employment.
• The stock options vest in 36 equal monthly installments starting March 1, 2024, also contingent upon continued employment.
• Following these transactions, Chadwick directly owns 46,758 shares of common stock and stock options for 80,548 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to positively as it aligns executive interests with company performance. The vesting schedules suggest a long-term commitment.

Positives

• The acquisition of RSUs and stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both RSUs and stock options are tied to continued employment, incentivizing the executive to remain with the company.

Future Outlook

The vesting schedules of the RSUs and stock options suggest a long-term commitment from the executive to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation tools for executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules described are fairly standard, with multi-year vesting periods to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning executive interests with the company's long-term success.
• Employees may see this as a reflection of the company's commitment to its leadership team.

Key Dates